JP2016527225A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527225A5
JP2016527225A5 JP2016526580A JP2016526580A JP2016527225A5 JP 2016527225 A5 JP2016527225 A5 JP 2016527225A5 JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016527225 A5 JP2016527225 A5 JP 2016527225A5
Authority
JP
Japan
Prior art keywords
antibody
kabat
seq
upa
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016526580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527225A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/065136 external-priority patent/WO2015007727A1/en
Publication of JP2016527225A publication Critical patent/JP2016527225A/ja
Publication of JP2016527225A5 publication Critical patent/JP2016527225A5/ja
Withdrawn legal-status Critical Current

Links

JP2016526580A 2013-07-15 2014-07-15 ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体 Withdrawn JP2016527225A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13176519 2013-07-15
EP13176519.0 2013-07-15
US201361847664P 2013-07-18 2013-07-18
US61/847,664 2013-07-18
PCT/EP2014/065136 WO2015007727A1 (en) 2013-07-15 2014-07-15 Antibodies that bind urokinase plasminogen activator

Publications (2)

Publication Number Publication Date
JP2016527225A JP2016527225A (ja) 2016-09-08
JP2016527225A5 true JP2016527225A5 (enExample) 2017-08-10

Family

ID=48783103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526580A Withdrawn JP2016527225A (ja) 2013-07-15 2014-07-15 ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体

Country Status (6)

Country Link
US (1) US9908944B2 (enExample)
EP (1) EP3022229A1 (enExample)
JP (1) JP2016527225A (enExample)
CN (1) CN105612183A (enExample)
TW (1) TW201536810A (enExample)
WO (1) WO2015007727A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
US11066482B2 (en) 2017-09-21 2021-07-20 Guy L. Reed Specific plasmin inactivation by anticatalytic antibody
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス, インコーポレイテッド Cd33、nkg2d、及びcd16に結合する多重特異性結合タンパク質、ならびにその使用方法
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020063823A1 (en) * 2018-09-27 2020-04-02 Zai Lab (Shanghai) Co., Ltd. Anti-pd-1 antibodies and uses thereof
CN110343665B (zh) * 2019-05-05 2023-07-14 吉林大学 一种car-t细胞及其应用
CA3158174A1 (en) * 2019-10-28 2021-05-06 Monash University Antibodies for binding plasmin
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
WO2022171196A1 (zh) * 2021-02-11 2022-08-18 兰州大学第二医院 抗cd87抗体及其特异性嵌合抗原受体
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
TW202606662A (zh) * 2024-04-26 2026-02-16 美商美國禮來大藥廠 蛋白質酪胺酸激酶7抗體及抗體藥物結合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453269A (en) 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
TW212184B (enExample) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US8062637B2 (en) 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
AU2002358921A1 (en) * 2001-07-10 2003-04-28 Omnio Ab Novel drug targets for arthritis
WO2003057881A1 (en) * 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
WO2005048822A2 (en) 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2006050177A2 (en) 2004-10-29 2006-05-11 The Regents Of The University Of Colorado Antibodies that bind urokinase-type plasminogen activator and epitopes therefor
CA2603264C (en) * 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
US8628773B2 (en) * 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins

Similar Documents

Publication Publication Date Title
JP2021514973A5 (enExample)
JP2024056687A5 (enExample)
JP2019122405A5 (enExample)
RU2017114341A (ru) Антитела к pd-l1, связывающие pd-l1 собаки
JP2016512551A5 (enExample)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2017528476A5 (enExample)
JP2010536384A5 (enExample)
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
PE20181051A1 (es) Anticuerpo anti-epha4
JP2013198490A5 (enExample)
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
JP2013091655A5 (enExample)
NZ585559A (en) Humanized antibodies against tl1a
PE20141186A1 (es) Proteinas de union al tnf-alfa
JP2017534577A5 (enExample)
JP2018527903A5 (enExample)
JP2017052784A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
WO2006103100A3 (en) Antibodies against ccr5 and uses thereof
JP2014512809A5 (enExample)
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
JP2016533763A5 (ja) ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
HRP20241013T1 (hr) Protutijela za kelatirane radionuklide